Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.
Eur Respir J
; 58(1)2021 07.
Article
em En
| MEDLINE
| ID: mdl-33574076
ABSTRACT
BACKGROUND:
Several studies have shown that statins have beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation.METHODS:
We performed a randomised double-blind placebo-controlled single-centre trial of simvastatin at a daily dose of 40â mg versus placebo in patients with Global Initiative for Chronic Obstructive Lung Disease criteria grades 2-4 at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12â months and the main outcome parameter was time to first exacerbation.RESULTS:
Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo median 341 versus 140â days (log-rank test p<0.001). Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34-0.75; p=0.001). Rate of exacerbations was significantly lower with simvastatin 103 (41%) versus 147 (59%) (p=0.003). The annualised exacerbation rate was 1.45â events per patient-year in the simvastatin group and 1.9 events per patient-year in the placebo group (incidence rate ratio 0.77, 95% CI 0.60-0.99). We found no effect on quality of life, lung function, 6-min walk test and high-sensitivity C-reactive protein. More patients dropped out in the simvastatin group compared to the placebo group (39 versus 29).CONCLUSION:
In our single-centre RCT, simvastatin at a dose of 40â mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Doença Pulmonar Obstrutiva Crônica
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Eur Respir J
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Áustria